Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures
Official title: Prospective Randomized Controlled Trial of Skin Closure Techniques in Oncological Cranial Neurosurgery: Interrupted Transdermal Sutures and Running Intradermal Suture.
Run by Medical University of Warsaw · NCT07413796 · Data updated 2026-11-12
This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 382 (estimated) |
| Sponsor | Medical University of Warsaw Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Warsaw, Masovian Voivodeship) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | February 2028 |
| Study ends | May 2028 |
| Registry record updated | May 20, 2026 |
| Trial ID | NCT07413796 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) scheduled for elective craniotomy for a supratentorial intracranial tumor who are not undergoing revision or emergency surgery and whose scalp incision does not involve forehead or facial regions.
✕Probably not a fit
Patients having revision craniotomies for recurrent tumors, emergency neurosurgical procedures, or scalp incisions that involve glabrous or facial skin are excluded and would not directly benefit from the results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults undergoing elective craniotomy for supratentorial intracranial tumors at the Medical University of Warsaw will have their scalp closed with either an absorbable running intradermal suture or a non-absorbable interrupted transdermal suture. Investigators will record wound healing outcomes, complications, and time to initiation of adjuvant therapy such as radiotherapy or chemotherapy. The protocol excludes revision surgeries, emergency procedures, and incisions involving the forehead or facial regions. Both techniques are commonly used but lack strong comparative data specifically in oncological neurosurgery.
Why it matters
Potential benefit: If one method shows faster or more reliable wound healing, patients could experience fewer wound complications and be able to start adjuvant therapy sooner.
How similar studies have gone: Comparisons of suture techniques exist in general surgery and some neurosurgical reports, but high-quality evidence specific to oncological neurosurgery is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female at least 18 years old * Qualified for a craniotomy due to supratentorial intracranial tumor Exclusion Criteria: * Revision surgery due to recurrent brain tumor * Emergency neurosurgical procedure * Scalp incision involving glabrous skin (e.g. forehead) or facial regions (e.g. eyebrow)
Where it's running
-
Department of Neurosurgery of Medical University of Warsaw
Warsaw, Masovian Voivodeship, Poland Recruiting
Study contacts
- Principal investigator: Michał Senger, M.D. — Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland
- Study coordinator: Michał Senger, M.D.
- Email: michal.senger@wum.edu.pl
- Phone: +48 791 760 040
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrospinal fluid leak after brain tumor surgery
This project will look at adults having planned supratentorial craniotomy for intracranial tumors to see how often cerebrospinal fluid leaks occur and what complications they cause.
-
Pharmacoscopy-guided treatment for refractory brain tumors
This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Sitagliptin plus bevacizumab for recurrent grade 4 glioma
This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.